Type 2 Diabetes

Updates to the ADA Standards of Medical Care emphasize the utility of SGLT2 inhibitors and GLP-1 agonists. Yet, initiation is lacking from prescribers.

Dr. Donna H. Ryan presents data on emerging pharmacological strategies that could aid patients in achieving optimal weight loss and prevent risk of cardiovascular events and diabetes.

While drivers of gestational diabetes are not fully evidenced, data shows how it's linked to great likelihood of type 2 diabetes and cardiovascular events.

Despite having lower burden of several cardiovasculard disease risk factors, cardiovascular mortality is higher in African Americans, which Dr. Dagogo-Jack attributes to disparities in patient care.

Dr. Peter Grant admits that the phenotypes surrounding certain cardiovascular diseases are complex, but notes treatments can be recommended based on individual patients’ complications.

Though the trial observing dapagliflozin for severe COVID-19 did not achieve statistical significance, investigators believe it showed the agent's benefit in acute illness.

In his presentation at TMIOA, Dr. Inzucchi referenced several diabetes medications and glucose management methods that resulted in a reduction of stroke risk in patients.

A 3-year study with more than 500 patients, results suggest none of the study participants had a BCVA worse than 0.3 (log MAR 0.48) due to diabetic retinopathy.

The FDA and FTC posted warnings to 10 companies for violating the Federal Food, Drug, and Cosmetic Act by selling dietary supplements claiming to cure, treat, mitigate, or prevent diabetes.

Mean age of diabetes diagnosis was 4 - 7 years earlier among non-Hispanic Black and Mexican American adults, in comparison to non-Hispanic White adults.

New data describes risk factors associated with increased prevalence of sexual dysfunction among patients with type 1 and type 2 diabetes.

Editorial advisory board member Dr. Paul Thompson reflects on how advances in diabetes management have impacted cardiovascular medicine and why staying abreast of these advances is essential to being a cardiologist in 2021.

Investigators noted a need for multidisciplinary interventions for prevention of diabetic ketoacidosis and hyperglycemic hyperosmolar state in patients with diabetes.

Dr. Paul Thompson reflects on how advances in diabetes management have bled over into the field of cardiology and offers perspective on why he believes staying abreast of these advances is an integral part of being a cardiologist today.

Bertram Pitt, MD, offers perspective on how he interprets data from both FIDELIO-DKD and FIGARO-DKD inform the use of finerenone in patients with diabetes and chronic kidney disease.

Results of a post hoc analysis of the TWILIGHT trial provide insight into the effects of ticagrelor monotherapy compared to dual therapy with aspirin in patients with concomitant CKD and diabetes.

Results of FIGARO-DKD were presented at ESC Congress 2021 and, combined with FIDELIO-DKD data, demonstrate the ability of finerenone to provide benefit across the spectrum of eGFR.

Sexual dysfunction in men was related to clinical factors, including erectile dysfunction, while women reported low emotional well-being and symptoms of anxiety.

Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.

Deepak Bhatt, MD, discusses a presentation he gave at ESC Congress 2021 on SGLT2, 1/2 inhibition and reflects on the potential for sotagliflozin to receive approval from the FDA based on data from SOLOIST-WHF and SCORED.

Professor Bertram Pitt discusses the results of FIGARO-DKD, what they add when combined with FIDELIO-DKD, and future research priorities moving forward in a Q&A with Practical Cardiology.

August's month in review features a pair of FDA approvals, new guidance on screening for gestational diabetes and T2D, a 3-part video series, and news on COVID-19, glucose control, and vitamin D levels.

Incidence of death from cardiovascular causes was lower in the finerenone group (458 of 3686 patients) compared to the placebo group (519 of 3666 patients).

FIGARO-DKD concluded use of finerenone was associated with a 13% reduction in the primary outcome, which investigators purport demonstrates the benefit of finerenone use in a population with milder chronic kidney disease than those included in FIDELIO-DKD.

The updated USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 - 75 years with conditions including overweight or obesity.

The US Preventive Services Task Force has issued a B-graded recommendation statement lowering their recommended age for screening for type 2 diabetes from 40 to 35 years.

Data from the SEARCH for Diabetes in Youth Study suggests the prevalence of type 1 diabetes among youths have increased by nearly 50% from 2001-2017 and prevalence of type 2 diabetes increased by more than 95% during the same period.

New data suggests patients with a history of diabetes, hypertension, or cardiovascular disease were at increased risk of worsening hypoxemia compared to their counterparts without these conditions.

A new meta-analysis by investigators from Johns Hopkins details the prevalence of UACR testing in patient populations at increased risk of albuminuria, suggesting less than 40% of patients with diabetes underwent UACR testing and this figure dropped to less than 5% among patients with hypertension.

A review article details the prevalence and impact of sleep disorders in patients with type 2 diabetes as well as providing an overview current treatment options and research needs.